

Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

9/5/23

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 5, 2023-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, Sept. 11, 2023 at 8:40 a.m. E.T. The fireside chat will be held at the Sheraton New York in New York, NY.

The presentation will be webcast live under the Events & Presentations section of the investor relations section of Sarepta's website at https://investorrelations.sarepta.com/events-presentations and will be archived there following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics

Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information

We routinely post information that may be important to investors in the 'For Investors' section of our website at <u>www.sarepta.com</u>. We encourage investors and potential investors to consult our website regularly for important information about us.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230905612978/en/

Investor:

lan Estepan, 617-274-4052 jestepan@sarepta.com

Media:

Tracy Sorrentino, 617-301-8566 tsorrentino@sarepta.com

Source: Sarepta Therapeutics, Inc.